Table 2.

Unadjusted incidence rates and cumulative incidence of events in patients newly treated with antifibrotic drugs

	Unadjusted incidence rate [95% CI] (per 100 person-years)	One-year cumulative incidence of event, % [95% CI]	Three-year cumulative incidence of event, % [95% CI]
All-cause mortality
Patients initiating pirfenidone	10.91 [8.81–13.51]	9.79 [7.41–12.56]	25.46 [19.60–31.71]
Patients initiating nintedanib	15.36 [12.13–19.44]	14.25 [10.81–18.14]	31.11 [21.16–41.56]
Acute respiratory-related hospital admissions
Patients initiating pirfenidone	26.99 [23.34–31.21]	22.85 [19.35–26.52]	48.26 [39.76–56.24]
Patients initiating nintedanib	30.70 [25.69–36.68]	27.46 [22.95–32.14]	43.62 [30.75–55.79]
Treatment discontinuation
Patients initiating pirfenidone	82.88 [75.27–91.26]	53.75 [50.13–57.22]	–
Patients initiating nintedanib	64.82 [56.85–73.91]	46.53 [41.96–50.97]	–

CI confidence interval